Structure Therapeutics reported Phase 2 results for aleniglipron, an oral GLP‑1 receptor agonist, showing substantial weight loss over 44 weeks that rivaled injectable competitors. Trial readouts indicate robust mean and placebo‑adjusted weight reductions across dose cohorts and a tolerability strategy that reduced early discontinuations by using slower up‑titration. Company commentary and published trial summaries place aleniglipron among emerging oral GLP‑1 candidates vying to capture market share opened by recent oral and injectable launches. Structure plans Phase 3 progression based on the Phase 2 efficacy and safety profile.